Phio Pharmaceuticals Corp. Stock News

Penny stocks, defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it's understandable why penny stocks attract inter

Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.

Phio Pharma (NASDAQ: PHIO ) stock is pulling back on Thursday after the immuno-oncology therapeutics company's shares underwent a major rally yesterday. Investors will note that the company's stock s

PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.

It's been a big day for investors in Phio Pharmaceuticals (NASDAQ: PHIO ), unfortunately on the downside. This afternoon, PHIO stock has declined nearly 20% on a couple of key announcements.

Phio Pharmaceuticals Corp. (PHIO) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th

Phio Pharmaceuticals Corp. (PHIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MARLBOROUGH, Mass. , April 18, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propri

Check these three penny stocks out as PHIO stock climbs The post 3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) The preclinical data ex

The French National Agency for the Safety of Medicines and Health Products has signed off Phio Pharmaceuticals Corp''s (NASDAQ: PHIO ) clinical trial with its lead product candidate, PH-762 in melanoma. The Company expects to dose the first patient in Q1 of 2022. PH-762 activates immune cells to recognize better and kill cancer cells. It reduces the Full story available on Benzinga.com

We're seeing major movement from some hot penny stocks today and are diving into all the recent news that has them on the rise! The post 3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gai

Phio Pharmaceuticals Corp (PHIO) shares closed today at 0.4% above its 52 week low of $0.96, giving the company a market cap of $13M. The stock is currently down 3.4% year-to-date, down 68.2% over the past 12 months, and down 86.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 16.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 37.5% The company's stock price performance over the past 12 months lags the peer average by 259.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Phio Pharmaceuticals Corp (PHIO) shares closed today at 0.4% above its 52 week low of $0.96, giving the company a market cap of $13M. The stock is currently down 3.4% year-to-date, down 66.2% over the past 12 months, and down 86.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 16.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 37.5% The company's stock price performance over the past 12 months lags the peer average by 249.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Phio Pharmaceuticals Corp (PHIO) shares closed 4.0% lower than its previous 52 week low, giving the company a market cap of $14M. The stock is currently down 60.2% year-to-date, down 59.9% over the past 12 months, and down 85.8% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 45.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 277.6% The company's stock price performance over the past 12 months lags the peer average by 284.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.